Laquinimod | Immunomodulator

CAS: 248281-84-7

Catalog Number:10-4971

Laquinimod (248281-84-7) is an immunomodulator1 that inhibits inflammation2 and autoimmunity3,4 via activation 

of the aryl hydrocarbon receptor (AhR)5. It has been investigated as a treatment for multiple sclerosis6 and has 

shown efficacy in Huntington’s disease models7,8.

CAS:248281-84-7

Catalog Number:10-4971

Activity:Immunomodulator

Chemical Names:5-Chloro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenylquinoline-3-carboxamide

Alternate Name:ABR-215062

Molecular Weight:356.81

Molecular Formula:C19H17ClN2O3

Solubility:Soluble in DMSO (>25 mg/ml)

Physical Properties:Off-white solid

Purity:98% HPLC

NMR (Conforms)Storage Temperature:-20°C

Stability:Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.

Shipping Code:RT

Safety Data Sheet:N/A

References/Citations:

Jönsson et al. (2004), Synthesis and Biological Evaluation of New 1,2-Dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for 

Treatment of Autoimmune Disorders: Structure-Activity Relationship; Med. Chem. 47 2075

Rothhammer et al. (2021); Aryl Hydrocarbon Receptor Activation in Astrocytes by Laquinimod Ameliorates Autoimmune 

Inflammation in the CNS, Neurol. Neuroimmunol. Neuroinflamm., 8 e946

Pitarokoili et al. (2014), Laquinimod exerts strong clinical and immunomodulatory effects in Lewis rat experimental autoimmune 

neuritis; Neuroimmunol., 274 38

Ott et al. (2019), Laquinimod, a prototypic quinoline-3-carboxamide and aryl hydrocarbon receptor agonist, utilizes CD155-

mediated natural killer/dendritic cell interaction to suppress CNS autoimmunity; Neuroinflammation, 16 49

Kaye et al. (2016), Laquinimod arrests experimental autoimmune encephalitis by activating the aryl hydrocarbon receptor; 

Natl. Acad. Sci. USA., 113 E6145

Thöne and Linker (2016), Laquinimod in the treatment of multiple sclerosis: a review of the data so far; Drug Des. Devel. 

Ther., 10 1111

Dobson et al. (2016), Laquinimod dampens hyperactive cytokine production in Huntington’s disease patient myeloid cells; 

Neurochem., 137 782

Garcia-Miralles et al. (2016), Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural 

improvements in the YAC128 model of Huntington disease; Rep., 6 31652